Biopharma Co. Transforming Injected Drugs Into Pills
Source: Dr. Ram Selvaraju  (9/7/22)
This Israeli firm recently attracted the attention of the US-based financial institution, H.C. Wainwright & Co., which launched analyst coverage of it. More >

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling
Source: Clive Maund  (9/7/22)
Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen. More >

Two Talks On New Cancer Drug Slated for Meeting This Week
Source: Dr. Tony Butler  (9/6/22)
The upcoming discussions pertain to a biopharma's clinical stage T-cell therapy as a treatment for solid tumors, noted a ROTH Capital Partners report. More >

Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?
Source: Streetwise Reports  (9/4/22)
One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August. More >

Denmark Co. To Buy US Biopharma Co. for $1.1 Billion
Source: Streetwise Reports  (9/2/22)
Forma Therapeutics Holdings Inc. shares traded 51% higher yesterday after the company reported it agreed to be acquired by Denmark's Novo Nordisk A/S in an all-cash deal for $20.00 per share. With the acquisition, Novo Nordisk aims to expand its global presence in the treatment of rare blood disorders and sickle cell disease. More >

Expert Rates Pharma Co. An Immediate Buy
Source: Chris Temple  (9/1/22)
Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough. More >

FDA OKs Biopharma to Trial New Cell Therapy
Source: Mitchell Kapoor  (8/30/22)
Now with clearance, the firm plans to commence a Phase 1 study of its lead candidate in patients with lymphoma by the end of this year, noted an H.C. Wainwright & Co. report. More >

Pharma Co. Plans IND Filing for Dry Eye Disease Drug in Q4/22
  (8/30/22)
Shares of OKYO Pharma Ltd. traded 23% higher after the company reported it intends to submit an IND to the U.S. FDA for its OK-101 for treating dry eye disease in Q4/22. Together with its manufacturing partner, AmbioPharm Inc., the firm is now preparing to initiate a phase 2 clinical study in Q1/23. More >

Delay in New Drug Filing Now Could Yield Benefits Later
Source: Hartaj Singh  (8/29/22)
The developer of genetic medicines is taking six more months to conduct longer preclinical safety studies involving its lead therapeutic, noted an Oppenheimer report. More >

ACC Recommends Approved Drug for Lowering LDL
Source: Joseph Pantginis  (8/29/22)
This same medicine is currently being evaluated in a global clinical trial from which topline results are expected in Q1/23, noted an H.C. Wainwright & Co. report. More >

Pharma Co. To Provide HHS With Smallpox Drug
Source: Streetwise Reports  (8/29/22)
Chimerix Inc. shares traded 8% higher after the company reported it has entered into a 10-year, $680 million contract with a U.S. Government health agency to deliver up to 1.7 million treatment courses of its TEMBEXA for use as a medical countermeasure for smallpox. More >

Biotech Co. Signs Option Agreement With Drug Co. to Find Ideal Ketamine Formula
Source: Streetwise Reports  (8/26/22)
A small biotech has taken further steps to deepen the intellectual property moat for its potentially revolutionary treatment for alcohol addiction. Find out which company it is and why one analyst has given it a CA$8 target price. More >

First Data Due by Year End 2022 From Study of New HAE Drug
Source: Hartaj Singh  (8/24/22)
Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report. More >

New Schizophrenia Drug Has Chance of Getting FDA Approved
Source: Dr. Thomas Shrader   (8/24/22)
The U.S. Food and Drug Administration's follow-up to the new drug application for this potential treatment suggests a possible green light based on unmet medical need, noted a BTIG report. More >

Hedge Fund Doubles Position in Biotech Co.
Source: Streetwise Reports  (8/23/22)
A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price — a 560% increase from the unit price in its recent placement. More >

Expert Sees Even More 'Good News' From Pharma Co.
Source: Clive Maund  (8/23/22)
Expert Clive Maund reviews the latest news with Algernon Pharmaceuticals Inc., including the recent successful closing of its financing. More >

Biotech Co. Has Multiple Shots on Goal
Source: Justin Kim  (8/22/22)
This developer of immunotherapies has a robust pipeline, several active clinical programs and, thus, numerous catalysts, noted an Oppenheimer report. More >

Price Target on Cancer Drug Co. Boosted
Source: Joseph Pantginis  (8/22/22)
The price target was increased by 66% to reflect the full potential opportunity of the biopharma's drug candidate for hepatocellular carcinoma, a key driver going forward, noted an H.C. Wainwright & Co. report. More >

Drug Developer Initiates Ph. 3 STGD1 Trial
Source: Streetwise Reports  (8/22/22)
Shares of Belite Bio Inc. traded 19% higher after the company reported it has initiated a pivotal Phase 3 clinical study in the U.S. for its LBS-008 for use in treating Stargardt disease. More >

Biopharma Co. Gains FDA Approval for Oral MDD Drug
Source: Streetwise Reports  (8/19/22)
Shares of Axsome Therapeutics Inc. traded 39% higher after the company reported that the U.S. FDA granted approval for its AUVELITYâ„¢ making it the first oral N-methyl D-aspartate (NMDA) receptor antagonist authorized for treating major depressive disorder in adults. More >

Healthcare Co. Brings Treatment to Canadian Alcohol Addiction Market
Source: Streetwise Reports  (8/18/22)
One healthcare company in the U.K. is bringing its proprietary Ketamine-assisted treatment for Alcohol Use Disorder to Canada. It's the second deal the company has made with a North American clinic operator this week. Find out why this won't be the last one. More >

Biotech Co. To Receive 66% Funding From UK Gov.
Source: Clive Maund  (8/17/22)
Expert Clive Maund reviews the latest update with Awakn Life Sciences Corp., including its recent rise in stock volume and the announcement that the company is to receive 66% funding support from the UK government for the development of its ketamine-assisted therapy treatment for alcohol use disorders. More >

Life Sciences Co. Gets Big Order for Livestock Feed Additive
Source: Joseph Gomes   (8/16/22)
This sale indicates the firm is continuing to forge a pathway into one of its large target markets, noted a Noble Capital Markets report. More >

Co. Pursuing Ketamine for Addiction Forms Partnership
Source: Andrew Partheniou  (8/16/22)
In landing this first licensing deal, the life sciences firm "shows good progress towards a potentially high-margin business," noted a Stifel report. More >

Co. Provides Ground-Floor Opportunity in Precision Oncology
Source: Joseph Pantginis  (8/15/22)
Nuvectis Pharma Inc recently announced quarterly financial results and is continuing to advance its precision oncology programs. H.C. Wainwright & Co. LLC advised in an earnings update that the firm offers significant upside potential as it is rapidly advancing its drug candidates through clinical development and is looking for ways to expand to markets outside of the U.S. H.C. Wainwright stated that it is reiterating its Buy rating and $21 price target for Nuvectis Pharma. More >